{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:54:30Z","timestamp":1781654070118,"version":"3.54.5"},"reference-count":74,"publisher":"Georg Thieme Verlag KG","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Complement activation is a consistent and predictable biological response to adeno-associated virus gene therapy, particularly after high-dose systemic administration. Early postdose laboratory changes, including mild thrombocytopenia, modest reductions in C3 and C4, and low-level elevations in complement activation markers, are commonly observed and generally reflect expected pharmacodynamic effects rather than toxicity in isolation. However, a subset of individuals progresses to complement-mediated endothelial injury and thrombotic microangiopathy, a rare but potentially severe complication. Despite increasing recognition of complement biology in gene therapy safety, laboratory monitoring practices remain inconsistent, and interpretation of complement biomarkers is often fragmented. Reliance on isolated measurements may obscure early pathologic trajectories, while functional assays are sensitive to preanalytical variability. Emerging data suggest that alternative pathway amplification governs severity across diverse initiating mechanisms and distinguishes self-limited complement activation from sustained endothelial injury. This article proposes a laboratory-centered framework that integrates complement biomarkers with hematologic and renal indices, emphasizing serial trends over isolated values. Standardized interpretation of complement testing is essential for early recognition of pathologic escalation and for maintaining patient safety as gene therapy expands across clinical settings.<\/jats:p>","DOI":"10.1055\/a-2887-9935","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T22:59:27Z","timestamp":1780527567000},"source":"Crossref","is-referenced-by-count":0,"title":["Laboratory Monitoring of Complement Activation in Gene Therapy: Analytical Pitfalls and Clinical Interpretation"],"prefix":"10.1055","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8047-338X","authenticated-orcid":false,"given":"Brandon M.","family":"Henry","sequence":"additional","affiliation":[{"name":"Evidence Generation and Translation Lab for Genetic Therapies (EvGenTx), Texas, United States","place":["San Antonio"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melvin Y.","family":"Rincon","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Cardiovascular de Colombia, Colombia","place":["Floridablanca"],"department":["Centro de Investigaciones"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9523-9054","authenticated-orcid":false,"given":"Giuseppe","family":"Lippi","sequence":"additional","affiliation":[{"name":"University degli Studi di Verona, Italy","place":["Verona"],"department":["Section of Clinical Biochemistry"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Proh\u00e1szka","sequence":"additional","affiliation":[{"name":"Fst Gyrgy Complement Diagnostic Laboratory and Research Laboratory, Semmelweis University, Budapest, Hungary","place":["Budapest"],"department":["Department of Internal Medicine and Hematology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Benoit","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Cincinnati, Ohio, United States","place":["Cincinnati"],"department":["Department of Pediatrics"]},{"name":"Cincinnati Children's Hospital Medical Center, Ohio, United States","place":["Cincinnati"],"department":["Division of Bone Marrow Transplantation & Immune Deficiency"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"e173510","DOI":"10.1172\/JCI173510","article-title":"Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies","volume":"134","author":"S M Salabarria","year":"2024","journal-title":"J Clin Invest"},{"issue":"09","key":"ref2","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.1016\/j.ymthe.2025.06.032","article-title":"Complement activation in a phase Ib study of fordadistrogene movaparvovec for Duchenne muscular dystrophy","volume":"33","author":"B J Byrne","year":"2025","journal-title":"Mol Ther"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1089\/hum.2023.194","article-title":"Complement system response to adeno-associated virus vector gene therapy","volume":"35","author":"E Kropf","year":"2024","journal-title":"Hum Gene Ther"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1089\/hum.2024.040","article-title":"Innate immune sensing of adeno-associated virus vectors","volume":"35","author":"D Cao","year":"2024","journal-title":"Hum Gene Ther"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jpeds.2020.11.054","article-title":"Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: a case series","volume":"231","author":"D H Chand","year":"2021","journal-title":"J Pediatr"},{"issue":"14","key":"ref6","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1182\/bloodadvances.2021006419","article-title":"Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy","volume":"6","author":"J Guillou","year":"2022","journal-title":"Blood Adv"},{"issue":"13","key":"ref8","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","article-title":"Death after high-dose rAAV9 gene therapy in a patient with Duchenne's muscular dystrophy","volume":"389","author":"A Lek","year":"2023","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1007102","DOI":"10.3389\/fimmu.2022.1007102","article-title":"Pitfalls in complement analysis: A systematic literature review of assessing complement activation","volume":"13","author":"R JMGE Brandwijk","year":"2022","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1089\/hum.2024.156","article-title":"Thrombotic microangiopathy associated with systemic adeno-associated virus gene transfer: review of reported cases","volume":"36","author":"G A Laforet","year":"2025","journal-title":"Hum Gene Ther"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.3389\/fimmu.2018.02237","article-title":"Interpretation of serological complement biomarkers in disease","volume":"9","author":"K N Ekdahl","year":"2018","journal-title":"Front Immunol"},{"issue":"03","key":"ref12","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/cpt.2966","article-title":"Adopting model-informed precision-dosing for eculizumab in transplant associated-thrombotic microangiopathy to gene therapies","volume":"114","author":"S Jodele","year":"2023","journal-title":"Clin Pharmacol Ther"},{"issue":"02","key":"ref13","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s40620-021-01122-x","article-title":"Estimation of kidney function in patients with primary neuromuscular diseases: is serum cystatin C a better marker of kidney function than creatinine?","volume":"35","author":"A Aldenbratt","year":"2022","journal-title":"J Nephrol"},{"issue":"11","key":"ref14","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.imbio.2016.06.008","article-title":"Complement analysis 2016: clinical indications, laboratory diagnostics and quality control","volume":"221","author":"Z Proh\u00e1szka","year":"2016","journal-title":"Immunobiology"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"962702","DOI":"10.1155\/2012\/962702","article-title":"Complement diagnostics: concepts, indications, and practical guidelines","volume":"2012","author":"B Nilsson","year":"2012","journal-title":"Clin Dev Immunol"},{"issue":"05","key":"ref16","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.bbmt.2018.01.009","article-title":"Early increase in complement terminal pathway activation marker sC5b-9 is predictive for the development of thrombotic microangiopathy after stem cell transplantation","volume":"24","author":"O Horv\u00e1th","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"02","key":"ref17","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/cei.12952","article-title":"Production of complement components by cells of the immune system","volume":"188","author":"R Lubbers","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"999021","DOI":"10.3389\/fimmu.2022.999021","article-title":"Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood","volume":"13","author":"C J Smith","year":"2022","journal-title":"Front Immunol"},{"issue":"12","key":"ref19","doi-asserted-by":"crossref","first-page":"e2250042","DOI":"10.1002\/eji.202250042","article-title":"Complement, complosome, and complotype: a perspective","volume":"53","author":"P Singh","year":"2023","journal-title":"Eur J Immunol"},{"issue":"11","key":"ref20","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","article-title":"Lethal immunotoxicity in high-dose systemic AAV therapy","volume":"31","author":"D Duan","year":"2023","journal-title":"Mol Ther"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement system part I - molecular mechanisms of activation and regulation","volume":"6","author":"N S Merle","year":"2015","journal-title":"Front Immunol"},{"issue":"09","key":"ref22","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ni.1923","article-title":"Complement: a key system for immune surveillance and homeostasis","volume":"11","author":"D Ricklin","year":"2010","journal-title":"Nat Immunol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1089\/hum.2023.018","article-title":"Complement activation by adeno-associated virus-neutralizing antibody complexes","volume":"34","author":"C West","year":"2023","journal-title":"Hum Gene Ther"},{"issue":"03","key":"ref24","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3390\/ijms25031566","article-title":"The lectin pathway of the complement system-activation, regulation, disease connections and interplay with other (proteolytic) systems","volume":"25","author":"J Dob\u00f3","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"01","key":"ref25","doi-asserted-by":"crossref","first-page":"cwad074","DOI":"10.1093\/glycob\/cwad074","article-title":"N-glycomic profiling of capsid proteins from adeno-associated virus serotypes","volume":"34","author":"Y Xie","year":"2024","journal-title":"Glycobiology"},{"issue":"11","key":"ref26","doi-asserted-by":"crossref","first-page":"7844","DOI":"10.1074\/jbc.M606326200","article-title":"Molecular interactions between MASP-2, C4, and C2 and their activation fragments leading to complement activation via the lectin pathway","volume":"282","author":"R Wallis","year":"2007","journal-title":"J Biol Chem"},{"issue":"01","key":"ref27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40164-021-00249-8","article-title":"Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy","volume":"10","author":"E Gavriilaki","year":"2021","journal-title":"Exp Hematol Oncol"},{"issue":"01","key":"ref28","first-page":"109","article-title":"The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation","volume":"21","author":"P J Lachmann","year":"1975","journal-title":"Clin Exp Immunol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.molimm.2019.07.032","article-title":"Is generation of C3(H2O) necessary for activation of the alternative pathway in real life?","volume":"114","author":"K N Ekdahl","year":"2019","journal-title":"Mol Immunol"},{"issue":"06","key":"ref30","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1084\/jem.20041497","article-title":"Platelet activation leads to activation and propagation of the complement system","volume":"201","author":"I Del Conde","year":"2005","journal-title":"J Exp Med"},{"issue":"05","key":"ref31","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.4049\/jimmunol.0902810","article-title":"Complement component C3 binds to activated normal platelets without preceding proteolytic activation and promotes binding to complement receptor 1","volume":"184","author":"O A Hamad","year":"2010","journal-title":"J Immunol"},{"issue":"03","key":"ref32","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2249.2004.02627.x","article-title":"The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation","volume":"138","author":"M Harboe","year":"2004","journal-title":"Clin Exp Immunol"},{"issue":"01","key":"ref33","doi-asserted-by":"crossref","first-page":"e1436","DOI":"10.1002\/cti2.1436","article-title":"The contribution of the alternative pathway in complement activation on cell surfaces depends on the strength of classical pathway initiation","volume":"12","author":"E C de Boer","year":"2023","journal-title":"Clin Transl Immunology"},{"issue":"03","key":"ref34","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1084\/jem.154.3.856","article-title":"Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3","volume":"154","author":"M K Pangburn","year":"1981","journal-title":"J Exp Med"},{"issue":"06","key":"ref35","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1128\/JVI.01990-07","article-title":"Complement is an essential component of the immune response to adeno-associated virus vectors","volume":"82","author":"A K Zaiss","year":"2008","journal-title":"J Virol"},{"issue":"01","key":"ref36","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1159\/000529734","article-title":"Measurement of complement activation via plasma-soluble C5b-9 comparison with terminal complement complex staining in a series of kidney biopsies","volume":"48","author":"C Wijaya","year":"2023","journal-title":"Kidney Blood Press Res"},{"issue":"10","key":"ref37","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1111\/ajt.12405","article-title":"Immune cell-derived C3a and C5a costimulate human T cell alloimmunity","volume":"13","author":"P Cravedi","year":"2013","journal-title":"Am J Transplant"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3389\/fimmu.2015.00257","article-title":"Complement system part II: role in immunity","volume":"6","author":"N S Merle","year":"2015","journal-title":"Front Immunol"},{"issue":"01","key":"ref39","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/hep.24625","article-title":"Toll-like receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors","volume":"55","author":"M H\u00f6sel","year":"2012","journal-title":"Hepatology"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1354055","DOI":"10.3389\/fimmu.2024.1354055","article-title":"Essential role of pre-existing humoral immunity in TLR9-mediated type I IFN response to recombinant AAV vectors in human whole blood","volume":"15","author":"N S Alakhras","year":"2024","journal-title":"Front Immunol"},{"key":"ref41","first-page":"79","article-title":"Control of cytokine production by human Fc gamma receptors: implications for pathogen defense and autoimmunity","volume":"6","author":"L TC Vogelpoel","year":"2015","journal-title":"Front Immunol"},{"issue":"08","key":"ref42","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nsmb.3427","article-title":"Regulator-dependent mechanisms of C3b processing by factor I allow differentiation of immune responses","volume":"24","author":"X Xue","year":"2017","journal-title":"Nat Struct Mol Biol"},{"issue":"10","key":"ref43","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.it.2012.06.001","article-title":"The complotype: dictating risk for inflammation and infection","volume":"33","author":"C L Harris","year":"2012","journal-title":"Trends Immunol"},{"issue":"03","key":"ref44","first-page":"175","article-title":"Ba and Bb fragments of factor B activation: fragment production, biological activities, neoepitope expression and quantitation in clinical samples","volume":"6","author":"W P Kolb","year":"1989","journal-title":"Complement Inflamm"},{"issue":"03","key":"ref45","doi-asserted-by":"crossref","first-page":"e28070","DOI":"10.1002\/pbc.28070","article-title":"The alternative complement pathway activation product Ba as a marker for transplant-associated thrombotic microangiopathy","volume":"67","author":"S Sartain","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"695037","DOI":"10.3389\/fimmu.2021.695037","article-title":"Early elevation of complement factor Ba is a predictive biomarker for transplant-associated thrombotic microangiopathy","volume":"12","author":"H Okamura","year":"2021","journal-title":"Front Immunol"},{"key":"ref47","first-page":"156","article-title":"Early- and late-phase activation of complement evaluated by plasma levels of C3d,g and the terminal complement complex","volume":"2","author":"T E Mollnes","year":"1985","journal-title":"Complement"},{"issue":"04","key":"ref48","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1309\/AJCPXPD7ZQXNTIAL","article-title":"Effect of blood sampling, processing, and storage on the measurement of complement activation biomarkers","volume":"143","author":"S Yang","year":"2015","journal-title":"Am J Clin Pathol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.cyto.2017.05.014","article-title":"Effect of the anticoagulant, storage time and temperature of blood samples on the concentrations of 27 multiplex assayed cytokines - consequences for defining reference values in healthy humans","volume":"97","author":"L T Henn\u00f8","year":"2017","journal-title":"Cytokine"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"660757","DOI":"10.3389\/fphar.2021.660757","article-title":"Pharmacological activities and mechanisms of hirudin and its derivatives - a review","volume":"12","author":"C Junren","year":"2021","journal-title":"Front Pharmacol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"113825","DOI":"10.1016\/j.jim.2025.113825","article-title":"Complement function and activation in human serum and plasma collected in different blood collection tubes","volume":"538","author":"L I Andersson","year":"2025","journal-title":"J Immunol Methods"},{"issue":"11","key":"ref52","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1007\/s10096-020-03955-z","article-title":"Complement levels in patients with bloodstream infection due to Staphylococcus aureus or gram-negative bacteria","volume":"39","author":"E M Eichenberger","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"02","key":"ref53","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/blood-2003-05-1530","article-title":"Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level","volume":"103","author":"H U Lutz","year":"2004","journal-title":"Blood"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"e00232","DOI":"10.1016\/j.plabm.2021.e00232","article-title":"Optimization of hemolysis, icterus and lipemia interference thresholds for 35 clinical chemistry assays","volume":"25","author":"C KM Ho","year":"2021","journal-title":"Pract Lab Med"},{"issue":"12","key":"ref55","doi-asserted-by":"crossref","first-page":"e29305","DOI":"10.1002\/jmv.29305","article-title":"Infusion reactions to adeno-associated virus (AAV)-based gene therapy: mechanisms, diagnostics, treatment and review of the literature","volume":"95","author":"K I Notarte","year":"2023","journal-title":"J Med Virol"},{"issue":"13","key":"ref56","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1182\/blood-2009-01-197640","article-title":"Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome","volume":"114","author":"L T Roumenina","year":"2009","journal-title":"Blood"},{"issue":"04","key":"ref57","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2014-03-564997","article-title":"Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults","volume":"124","author":"S Jodele","year":"2014","journal-title":"Blood"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"569291","DOI":"10.3389\/fmed.2020.569291","article-title":"Validation of early increase in complement activation marker sC5b-9 as a predictive biomarker for the development of thrombotic microangiopathy after stem cell transplantation","volume":"7","author":"B Mez\u00f6","year":"2020","journal-title":"Front Med (Lausanne)"},{"issue":"10","key":"ref59","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s40264-021-01107-6","article-title":"Clinical trial and postmarketing safety of onasemnogene abeparvovec therapy","volume":"44","author":"J W Day","year":"2021","journal-title":"Drug Saf"},{"issue":"06","key":"ref60","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1182\/blood-2005-06-2373","article-title":"Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease","volume":"107","author":"G J Kato","year":"2006","journal-title":"Blood"},{"issue":"04","key":"ref61","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3324\/haematol.2009.007229","article-title":"Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization","volume":"95","author":"A Hill","year":"2010","journal-title":"Haematologica"},{"issue":"04","key":"ref62","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1161\/HYPERTENSIONAHA.107.103127","article-title":"Association between thrombotic microangiopathy and reduced ADAMTS13 activity in malignant hypertension","volume":"51","author":"B JH van den Born","year":"2008","journal-title":"Hypertension"},{"issue":"06","key":"ref63","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1111\/ijlh.13682","article-title":"2021 update of the 2012 ICSH recommendations for identification, diagnostic value, and quantitation of schistocytes: impact and revisions","volume":"43","author":"G Zini","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"ref64","first-page":"203","article-title":"Corticosteroids significantly increase serum cystatin C concentration without affecting renal function in symptomatic heart failure","volume":"62","author":"J L Zhai","year":"2016","journal-title":"Clin Lab"},{"issue":"06","key":"ref65","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/mt.2011.3","article-title":"A potential role of distinctively delayed blood clearance of recombinant adeno-associated virus serotype 9 in robust cardiac transduction","volume":"19","author":"N M Kotchey","year":"2011","journal-title":"Mol Ther"},{"issue":"04","key":"ref66","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1177\/01926233221101309","article-title":"Intrathecal sc-AAV9-CB-GFP: systemic distribution predominates following single-dose administration in cynomolgus macaques","volume":"50","author":"E K Meseck","year":"2022","journal-title":"Toxicol Pathol"},{"issue":"299","key":"ref67","doi-asserted-by":"crossref","first-page":"299rv4","DOI":"10.1126\/scitranslmed.aaa7322","article-title":"Immune-mediated pathology in Duchenne muscular dystrophy","volume":"7","author":"A S Rosenberg","year":"2015","journal-title":"Sci Transl Med"},{"issue":"05","key":"ref68","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1161\/CIRCHEARTFAILURE.114.001105","article-title":"Danon disease: clinical features, evaluation, and management","volume":"7","author":"R S D'souza","year":"2014","journal-title":"Circ Heart Fail"},{"issue":"01","key":"ref69","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12995-024-00429-2","article-title":"Exploring work ability, psychosocial job demands and resources of employees in low-skilled jobs: a German cross-sectional study","volume":"19","author":"A Kaboth","year":"2024","journal-title":"J Occup Med Toxicol"},{"issue":"09","key":"ref70","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1203\/00006450-197909000-00019","article-title":"Serum complement levels in infancy: age related changes","volume":"13","author":"C A Davis","year":"1979","journal-title":"Pediatr Res"},{"issue":"04","key":"ref71","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/sji.12154","article-title":"Complement profile in neonates of different gestational ages","volume":"79","author":"A S Grumach","year":"2014","journal-title":"Scand J Immunol"},{"issue":"05","key":"ref72","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.3390\/ijms24054919","article-title":"Imbalanced inflammatory responses in preterm and term cord blood monocytes and expansion of the CD14+CD16+ subset upon toll-like receptor stimulation","volume":"24","author":"K Glaser","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"23","key":"ref73","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"C M Legendre","year":"2013","journal-title":"N Engl J Med"},{"issue":"06","key":"ref74","doi-asserted-by":"crossref","first-page":"269","DOI":"10.5414\/CP204176","article-title":"A randomized, double-blind, three-arm, parallel group, single-dose phase I study to evaluate the pharmacokinetic similarity between SB12 (a proposed eculizumab biosimilar) and eculizumab (Soliris) in healthy subjects","volume":"60","author":"H A Lee","year":"2022","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"01","key":"ref75","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/imr.13147","article-title":"C3-dependent effector functions of complement","volume":"313","author":"A Zarantonello","year":"2023","journal-title":"Immunol Rev"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2887-9935.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:13:16Z","timestamp":1781651596000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2887-9935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":74,"URL":"https:\/\/doi.org\/10.1055\/a-2887-9935","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,3]]},"published":{"date-parts":[[2026,6,3]]}}}